Efficacy of intradermal tranexamic acid in melasma

Authors

  • Nadia Sultan Department of Dermatology, Rahbar Medical and Dental College, Lahore.
  • Muhammad Usman Naeem Punjab Rangers Teaching Hospital, Lahore.
  • Khadija Mohsin Final Year MBBS, Rahber Medical and Dental College, Lahore.
  • Saima Rehman Saidu Medical College, Swat.
  • Ghazala Butt Department of Dermatology, King Edward Medical University/ Mayo Hospital, Lahore.
  • Mahwash Rana Department of Dermatology, Continental Medical College, Lahore.

DOI:

https://doi.org/10.66344/jpad.33.2.2023.2486

Keywords:

Melasma; Tranexamic acid (TA); Intradermal microinjections

Abstract

Objective To determine the efficacy of intradermal tranexamic acid (TA) in the patients of melasma.   Methods This study was conducted in Dermatology OPD, Punjab Rangers Teaching Hospital over a period of 4 months from 14-08-2022 to 14-12-2022. A total number of 32 patients of melasma were enrolled after informed written consent. 2mL of concentrated tranexamic acid (50mg/ml) was injected intradermally, 1 ml on either side of face 1cm apart over the affected area.  A total of 4 sessions were carried out, followed after every 2 weeks. Results were interpreted on the basis of MASI scoring before, during and after completion of the sessions. A mild topical steroid application was advised for 2 days. Sunscreen application was essentially prescribed.   Results  Out of 32 enrolled patients of melasma, 56% showed 61-100% reduction in MASI scoring, which constituted a majority.   Conclusion We concluded that un-diluted intra dermal tranexamic acid is an excellent treatment modality for treatment of melasma without any side effects.  

References

Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65(4):699-714.

Handel AC, Lima PB, Tonolli VM, Miot LD, Miot HA. Risk factors for facial melasma in women: A case-control study. Br J Dermatol. 2014;171:588-94.

Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1:261-8.

Li D, Shi Y, Li M et al. Tranexamic acid can treat ultraviolet radiation-induced pigmentation in guinea pigs. Eur J Dermatol. 2010;20(3):289-92.

Perper M, Eber AE, Fayne R. Tranexamic acid in the treatment of Melasma. Am J Clin Dermatol. 2017;18(3):373-81.

Kalluri H, Banga AK. Microneedles and transdermal drug delivery. J Drug Delivery Sci Technol. 2009;19:303-10.

M. Rodrigues and A. G. Pandya. Melasma: Clinical diagnosis and management options. Australasian J Dermatol. 2015;56(3):151-63

Guinot C, Chefaii S, Latreille J, Dhaoui MA, Youssef S, Jaber K et al. Aggravating factors for melasma: aprospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24:1060-9.

D. Li, Y. Shi, M. Li et al. Tranexamic acid can treat ultraviolet radiation-induced pigmentation in guinea pigs. J Eur Acad Dermatol Venereol. 2010;20:289-92.

L. Budamakuntla, E. Loganathan, D. Suresh et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melisma. J Cut Aesth Surg. 2013;6(3):139.

Kourtney Pony, Kiyanna Williams, A Multimodal Approach to Melasma. Advances in Cosmetic Surgery. 2022;5:1-8.

V. Lajevardi, A. Ghayoumi, R. Abedini et al. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up. J Cosmet Dermatol. 2017;16(2):235-42.

S. J. Kim, J.-Y. Park, T. Shibata, R. Fujiwara, and H. Y. Kang. Efficacy and possible mechanisms of topical tranexamic acid in melisma. Clin Exp Dermatol. 2016;41(5):480-5.

Downloads

Published

2023-07-02

How to Cite

1.
Nadia Sultan, Muhammad Usman Naeem, Khadija Mohsin, Saima Rehman, Ghazala Butt, Mahwash Rana. Efficacy of intradermal tranexamic acid in melasma. J Pak Assoc Dermatol [Internet]. 2023Jul.2 [cited 2026Apr.12];33(2):553-8. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2486

Issue

Vol. 33 No. 2 (2023): April-June

Section

Original Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

Most read articles by the same author(s)

1 2 > >>